CONJUGATE vaccine technology strengthened and accelerated antibody responses against influenza virus antigens in a preclinical murine study, supporting further evaluation of the iBoost platform as a potential strategy for next-generation influenza vaccine development.
Seasonal influenza continues to pose a major clinical and public health challenge, partly because current vaccines often generate strain-specific immunity that may be weakened by antigenic drift, waning immunity, and mismatch between vaccine and circulating strains. The study evaluated whether a chimeric designer peptide, derived from bacterial immunogens and used within the iBoost platform, could enhance responses to influenza hemagglutinin and neuraminidase antigens.
Researchers developed CDP-H1 and CDP-N1 vaccine constructs using hemagglutinin and neuraminidase sequences from the A/Wisconsin/588/2019 H1N1 strain. These were compared with unconjugated H1 and N1 constructs in BALB/c mice following prime and booster immunization.
Faster Antibody Responses With Conjugate Vaccine Constructs
The conjugate vaccine constructs induced stronger humoral responses than the unconjugated antigens. CDP-H1 generated a robust H1-specific immunoglobulin response by day 21, while CDP-N1 produced a marked increase in N1-specific antibodies as early as day 7.
Antibody titers remained higher in the CDP-H1 and CDP-N1 groups than in the H1 and N1 groups two weeks after booster administration. The conjugate vaccine approach also broadened IgG subclass distribution, maintaining strong IgG1 responses while increasing IgG2a, IgG2b, and IgG3 levels. This pattern may indicate greater functional diversity, including potential Fc-mediated effector mechanisms such as antibody-dependent cellular cytotoxicity, opsonization, and complement activation.
Influenza Vaccine Breadth Requires Further Testing
Functional assessment showed that CDP-H1 elicited detectable hemagglutination inhibition activity against multiple H1 strains and some H3 activity, although differences versus H1 alone were not statistically significant in this assay. CDP-N1 induced antibodies with binding reactivity to N2, suggesting cross-reactive potential.
The findings remain preliminary. The study did not include in vivo challenge assays, long-term immune follow-up, neuraminidase inhibition testing, or comparison with a licensed influenza vaccine. The H1 construct also appeared limited by epitope presentation, indicating that structural optimization may be needed.
Overall, the results suggest that conjugate vaccine technology may improve the magnitude, speed, and quality of antibody responses to influenza antigens. Further studies should assess durability, functional protection, and translational relevance in models that better reflect human pre-existing influenza immunity.
Reference
Myburgh L et al. Conjugate vaccine technology enhances responses to influenza virus. Vaccine. 2026;86:128728.
Featured Image: aleksmark2016 on Adobe Stock.
